Compare · IQV vs ONMD
IQV vs ONMD
Side-by-side comparison of IQVIA Holdings Inc. (IQV) and OneMedNet Corp (ONMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IQV and ONMD operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- IQV is the larger of the two at $30.66B, about 815.8x ONMD ($37.6M).
- Over the past year, IQV is up 19.2% and ONMD is up 86.4% - ONMD leads by 67.1 points.
- IQV has been more active in the news (5 items in the past 4 weeks vs 2 for ONMD).
- IQV has more recent analyst coverage (25 ratings vs 0 for ONMD).
- Company
- IQVIA Holdings Inc.
- OneMedNet Corp
- Price
- $183.69+0.14%
- $0.71+4.08%
- Market cap
- $30.66B
- $37.6M
- 1M return
- +2.59%
- -27.82%
- 1Y return
- +19.22%
- +86.35%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- 2021
- News (4w)
- 5
- 2
- Recent ratings
- 25
- 0
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest IQV
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Announces Pricing of Senior Notes
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Announces Offering of Senior Notes
- IQVIA CEO to Speak at Jefferies Global Healthcare Conference
- IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
- SEC Form 4 filed by Director Wims Morris Leslie
- SEC Form 4 filed by Director Goggins Colleen A
- SEC Form 4 filed by Director Fasano Jim
- SEC Form 4 filed by Director Danhakl John G
Latest ONMD
- OneMedNet Surpasses 90 Million Patient Journeys and 270 Million Studies within its Network
- Director Kosasa Thomas bought $250,000 worth of shares (268,817 units at $0.93), increasing direct ownership by 2% to 16,930,144 units (SEC Form 4)
- SEC Form 424B3 filed by OneMedNet Corp
- SEC Form 10-Q filed by OneMedNet Corp
- Amendment: SEC Form 10-K/A filed by OneMedNet Corp
- Chief Medical Officer Yu Jeffrey was granted 219,429 shares and bought $750,000 worth of shares (903,614 units at $0.83), increasing direct ownership by 15% to 8,449,266 units (SEC Form 4)
- Director Kosasa Thomas bought $749,999 worth of shares (876,136 units at $0.86), increasing direct ownership by 6% to 16,661,327 units (SEC Form 4)
- OneMedNet Goes Live with 80 Million Patient Journeys and Billions of Records
- OneMedNet Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- OneMedNet Announces Strong 2025 Financials and Advances AI-Driven iRWD™ powered by Palantir Foundry enabling Conversational Search on Real-Time Medical Data